Biology Reference
In-Depth Information
[74] Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab
for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J
Hematol 2009;90:253-60.
[75] von Bonin M, Oelschlagel U, Radke J, Stewart M, Ehninger G, Bornhauser M, et al.
Treatment of chronic steroid-refractory graft-versus-host disease with low-dose ritux-
imab. Transplantation 2008;86:875-9.
[76] Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of
refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant
2007;40:273-7.
[77] Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed
by monthly rituximab treatment for steroid-refractory chronic graft-versus-host
disease: results from a prospective, multicenter, phase II study. Haematologica
2010;95:1935-42.
[78] Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of
B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114:4919-27.
[79] She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, et al. Altered Toll-like
receptor 9 responses in circulating B cells at the onset of extensive chronic
graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:386-97.
[80] Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, et al. Donor
B-cell alloantibody deposition and germinal center formation are required for
the development of murine chronic GVHD and bronchiolitis obliterans. Blood
2011;119:1570-80.
[81] Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and
safety of belimumab in patients with active systemic lupus erythematosus: a ran-
domised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
[82] Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables
survival of transitional and mature B cells through distinct mediators. J Immunol
2002;168:5993-6.
[83] Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell
survival. Annu Rev Immunol 2003;21:231-64.
[84] Mackay F, Figgett WA, Saulep D, Lepage M, Hibbs ML. B-cell stage and context-depen-
dent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev
2010;237:205-25.
[85] Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF res-
cues self-reactive B cells from peripheral deletion and allows them to enter forbidden
follicular and marginal zone niches. Immunity 2004;20:785-98.
[86] Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell ho-
meostasis requires B cell activation factor production by radiation-resistant cells. J Exp
Med 2003;198:937-45.
[87] Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B
cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B
cell physiology. J Immunol 2004;173:2245-52.
[88] Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, et al. High
levels of B-cell activating factor in patients with active chronic graft-versus-host
disease. Clin Cancer Res 2007;13:6107-14.
[89] Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K, et al. Elevat-
ed numbers of immature/transitional CD21− B lymphocytes and deficiency of memory
CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood
Marrow Transplant 2008;14:208-19.
[90] Kuzmina Z, Greinix HT, Weigl R, Kormoczi U, Rottal A, Frantal S, et al. Significant dif-
ferences in B-cell subpopulations characterize patients with chronic graft-versus-host
disease-associated dysgammaglobulinemia. Blood 2011;117:2265-74.
[91] Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snavely J, Chen H, et al. Genetic
variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood
2011;118:1140-4.
[92] Fedoriw Y, Samulksi TD, Deal AM, et al. Bone marrow B cell precursor number after
allogeneic stem cell transplantation and GVHD development. Biol Blood Marrow
Transplant 2012;18:968-73.
[93] Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-
leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
[94] Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, et al. Remission
of relapsed leukaemia during a graft-versus-host reaction: a “graft-versus-leukaemia
reaction” in man? Lancet 1978;2:537-40.
[95] Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileuke-
mic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
N Engl J Med 1979;300:1068-73.
322
Search WWH ::
Custom Search